Psychotropic Profile of S 17092, a Prolyl Endopeptidase Inhibitor, Using Quantitative EEG in Young Healthy Volunteers
Authors:
- P. MorainPMP. Morain
- P.H. BoeijingaPBP.H. Boeijinga
- A. DemazièresADA. Demazières
- G. De NanteuilGNG. De Nanteuil
- R. LuthringerRLR. Luthringer
- 14 August 2007
- journal article
- clinical trial
- Published by S. Karger AG in Neuropsychobiology
- Vol. 55 (3-4) , 176-183
Abstract
The central activity of S 17092, a prolyl endopeptidase (PEP) inhibitor, was investigated by quantitative electroencephalography (qEEG) in 48 young healthy men participating in a double-blind, randomized, placebo-controlled, cross-over study. S 17092 (100, 200, 400 or 600 mg) and placebo were administered once daily for 10 days in a rising multiple-dose scheme. EEG recordings were performed before and repeatedly from 0.5 to 24 h after dose on day 1 and day 10. PEP activity in plasma was also measured for the same periods. S 17092 appeared as a potent inhibitor of PEP activity at all doses, after both single and repeated administrations. EEG changes after acute doses were slight and of short duration, mainly characterized by increased relative alpha 1 power, suggesting a vigilance-promoting EEG profile. After repeated doses and more strikingly after a superimposed dose, increases in relative alpha 1 power were still present with additional increase in relative delta power and decreases in absolute fast alpha, fast beta, theta powers and total power at all doses. These EEG findings suggest that S 17092 might possess some mood-stabilizing potential in addition to its cognition-enhancing properties.Keywords
This publication has 20 references indexed in Scilit:
- How can the mood stabilizer VPA limit both mania and depression?Molecular and Cellular Neuroscience, 2005
- Effect of Prolyl Endopeptidase Inhibition on Arginine‐Vasopressin and Thyrotrophin‐Releasing Hormone Catabolism in the Rat BrainJournal of Neuroendocrinology, 2005
- S 17092: A Prolyl Endopeptidase Inhibitor as a Potential Therapeutic Drug for Memory Impairment. Preclinical and Clinical StudiesCNS Drug Reviews, 2002
- Effects of the Prolyl Endopeptidase Inhibitor S 17092 on Cognitive Deficits in Chronic Low Dose MPTP-Treated MonkeysNeuropsychopharmacology, 2002
- Pharmacodynamic and pharmacokinetic profile of S 17092, a new orally active prolyl endopeptidase inhibitor, in elderly healthy volunteers. A phase I studyBritish Journal of Clinical Pharmacology, 2000
- S 17092-1, a Highly Potent, Specific and Cell Permeant Inhibitor of Human Proline EndopeptidaseBiochemical and Biophysical Research Communications, 1999
- CENTRAL NERVOUS SYSTEM EFFECTS OF GINKGO BILOBA, A PLANT EXTRACTAmerican Journal of Therapeutics, 1996
- Pharmacoelectroencephalographic Profile of Befloxatone, a New Reversible MAO-A Inhibitor, in Healthy SubjectsNeuropsychobiology, 1996
- Lower serum prolyl endopeptidase enzyme activity in major depression: Further evidence that peptidases play a role in the pathophysiology of depressionBiological Psychiatry, 1994
- Statistical Decision Tree: A Tool for Studying Pharmaco-EEG Effects of CNS-Active DrugsNeuropsychobiology, 1994